347 related articles for article (PubMed ID: 34127512)
1. Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer.
DeNicola GM; Shackelford DB
Cold Spring Harb Perspect Med; 2021 Nov; 11(11):. PubMed ID: 34127512
[TBL] [Abstract][Full Text] [Related]
2. Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer.
Davidson SM; Papagiannakopoulos T; Olenchock BA; Heyman JE; Keibler MA; Luengo A; Bauer MR; Jha AK; O'Brien JP; Pierce KA; Gui DY; Sullivan LB; Wasylenko TM; Subbaraj L; Chin CR; Stephanopolous G; Mott BT; Jacks T; Clish CB; Vander Heiden MG
Cell Metab; 2016 Mar; 23(3):517-28. PubMed ID: 26853747
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
4. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
5. Integrated 18F-fluorodeoxyglucose-positron emission tomography/dynamic contrast-enhanced computed tomography to phenotype non-small cell lung carcinoma.
Shastry M; Miles KA; Win T; Janes SM; Endozo R; Meagher M; Ell PJ; Groves AM
Mol Imaging; 2012; 11(5):353-60. PubMed ID: 22954179
[TBL] [Abstract][Full Text] [Related]
6. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Chen Z; Cheng K; Walton Z; Wang Y; Ebi H; Shimamura T; Liu Y; Tupper T; Ouyang J; Li J; Gao P; Woo MS; Xu C; Yanagita M; Altabef A; Wang S; Lee C; Nakada Y; Peña CG; Sun Y; Franchetti Y; Yao C; Saur A; Cameron MD; Nishino M; Hayes DN; Wilkerson MD; Roberts PJ; Lee CB; Bardeesy N; Butaney M; Chirieac LR; Costa DB; Jackman D; Sharpless NE; Castrillon DH; Demetri GD; Jänne PA; Pandolfi PP; Cantley LC; Kung AL; Engelman JA; Wong KK
Nature; 2012 Mar; 483(7391):613-7. PubMed ID: 22425996
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer.
Liao ZX; Kempson IM; Hsieh CC; Tseng SJ; Yang PC
Drug Discov Today; 2021 Nov; 26(11):2508-2514. PubMed ID: 34325010
[TBL] [Abstract][Full Text] [Related]
8. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment.
Kerk SA; Papagiannakopoulos T; Shah YM; Lyssiotis CA
Nat Rev Cancer; 2021 Aug; 21(8):510-525. PubMed ID: 34244683
[TBL] [Abstract][Full Text] [Related]
9. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Biochim Biophys Acta; 2016 Dec; 1866(2):177-188. PubMed ID: 27600832
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
11. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
[TBL] [Abstract][Full Text] [Related]
12. Prognostic molecular markers in non-small cell lung cancer.
Nikliński J; Niklińska W; Laudanski J; Chyczewska E; Chyczewski L
Lung Cancer; 2001 Dec; 34 Suppl 2():S53-8. PubMed ID: 11720742
[TBL] [Abstract][Full Text] [Related]
13. Early recognition of lung cancer by integrin targeted imaging in K-ras mouse model.
Ermolayev V; Mohajerani P; Ale A; Sarantopoulos A; Aichler M; Kayser G; Walch A; Ntziachristos V
Int J Cancer; 2015 Sep; 137(5):1107-18. PubMed ID: 25450481
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer in 2014: optimizing lung cancer treatment approaches.
Rosell R; Karachaliou N
Nat Rev Clin Oncol; 2015 Feb; 12(2):75-6. PubMed ID: 25533943
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Dependencies in RAS-Driven Cancers.
Kimmelman AC
Clin Cancer Res; 2015 Apr; 21(8):1828-34. PubMed ID: 25878364
[TBL] [Abstract][Full Text] [Related]
16. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
17. Integrated multi-omics characterization of KRAS mutant colorectal cancer.
Chong W; Zhu X; Ren H; Ye C; Xu K; Wang Z; Jia S; Shang L; Li L; Chen H
Theranostics; 2022; 12(11):5138-5154. PubMed ID: 35836817
[TBL] [Abstract][Full Text] [Related]
18. Metabolic rewiring in mutant Kras lung cancer.
Kerr EM; Martins CP
FEBS J; 2018 Jan; 285(1):28-41. PubMed ID: 28570035
[TBL] [Abstract][Full Text] [Related]
19. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer.
Leithner K; Hrzenjak A; Trötzmüller M; Moustafa T; Köfeler HC; Wohlkoenig C; Stacher E; Lindenmann J; Harris AL; Olschewski A; Olschewski H
Oncogene; 2015 Feb; 34(8):1044-50. PubMed ID: 24632615
[TBL] [Abstract][Full Text] [Related]
20. Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer.
Momcilovic M; Bailey ST; Lee JT; Zamilpa C; Jones A; Abdelhady G; Mansfield J; Francis KP; Shackelford DB
J Vis Exp; 2018 Jul; (137):. PubMed ID: 30080208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
